IBAB Ion Beam Applications SA

Steri-Tek to boost sterilization capacity of its Texas-based center fivefold with IBA’s X-ray irradiation system

Steri-Tek to boost sterilization capacity of its Texas-based center fivefold with IBA’s X-ray irradiation system

Louvain-la-Neuve, Belgium, June 18, 2025 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with Steri-Tek, a growing irradiation services provider, to install a fully-integrated Be Wide X-ray Solution.

IBA’s solution will be installed at Steri-Tek’s service center near Dallas-Fort Worth Metro Area, Texas, which was opened in 2023. This strategically located facility is positioned to serve a growing customer base, as well as creating logistical efficiencies. The addition of the Be Wide solution to their existing X-ray sterilization offering will increase Steri-Tek’s processing capacity fivefold, by enabling the sterilization of full pallets with a wider range of product densities, significantly improving throughput and scalability.  

The system provided by IBA will enhance Steri-Tek’s service offering to medical device manufacturers across North America. It will also help the company to ensure a seamless transition to IBA's Rhodotron®-based X-ray technology in line with their growth strategy. It is expected to be fully operational by the end of 2027. The typical price for a Be Wide X-ray Solution with customization ranges from EUR 16 million to EUR 19 million, depending on the configuration and options. A first payment has been received by IBA.

Larry Nichols, Chief Executive Officer of Steri-Tek, commented: "The integration of IBA's Be Wide X-ray Solution into our newest facility is a transformative step, enhancing our ability to serve customers with a high-volume sterilization capacity while strengthening our presence in North America."

Thomas Servais, President of IBA Industrial, added: "This collaboration with Steri-Tek underscores the increasing demand for scalable, high-capacity sterilization solutions. We are proud to support their expansion with cutting-edge technology and extensive service support, ensuring they stay ahead of industry demands."

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About Steri-Tek 

Steri-Tek, based in Fremont, CA, with a facility in Lewisville, TX is a high-volume E-beam/X-Ray contract sterilizer and R&D innovation center serving the medical device, biotech, pharmaceutical and other industries. Steri-Tek is an ISO 11137 and ISO 13485 certified, FDA registered, DEA licensed as well as State of California and Texas Medical Device and Drug Manufacturing licensed facilities. The California facility boasts two state-of-the-art 10 MeV, 20 KW linear accelerators. The Texas facility utilizes two state-of-the-art 10 MeV, 30 KW linear accelerators.  Both offer simultaneous beam processing that allows for high volume production, providing uniform dose to the product without having to rotate the customer’s boxes. This DualBeam™ configuration significantly increases efficiencies, expands product options, and serves as an effective back-up for the accelerators. Steri-Tek has developed a proprietary system for radiation sensitive materials such as drugs/biologics, combination devices, bioabsorbables, implantables, advanced polymers and other complex products. 

CONTACTS

Olivier Lechien

Corporate Communication Director



ICR Healthcare

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
18/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – Transparency Notification

IBA – Transparency Notification (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve (Belgium), 22 September 2025, 06:00 PM Summary of the notification IBA (Ion Beam Applications S.A - EURONEXT - Reuters IBAB.BR - Bloomberg IBAB.BB), the world leader in particle accelerator technology, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to a notification dated Tuesday 16 September 2025 and received on Thursday ...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (Article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve (Belgique), le 22 septembre 2025, 18h00 Résumé de la notification IBA (Ion Beam Applications S.A. - EURONEXT - Reuters IBAB.BR - Bloomberg IBAB.BB), le leader mondial de la technologie d’accélération de particules, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la sui...

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 10, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 3, 2025. In its notification, Marcel Jo Maschmeyer ind...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 10 septembre 2025, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçu...

Michiel Declercq
  • Michiel Declercq

IBA 1H25 Conference call feedback & model update

IBA reported good 1H25 results, with revenues up 40% to € 304.9m (kbcse: € 274.6m) driven by strong backlog conversion in PT as well as OA. However, as most of the conversion relates to legacy lower margin contracts in Spain and China, the gross profit increase of +27% to € 90.0m (kbcse: € 93.4m) and REBIT of € 10.6m (kbcse: € 10.3m) were broadly in line with our estimates. However net cash significantly deteriorated on the back of WC investments, as anticipated. We are pleased to see IBA reiter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch